In a study article published in Nature Plants scientific journal, and followed by a special review in the journal's News & Views, Weizmann Institute scientists revealed a step-by-step production of cannabinoids in the Helichrysum umbraculigerum plant.

The study, led by Dr. Shirley (Paula) Berman, in the professor Asaph Aharoni lab of the Weizmann Institute Plant and Environmental Sciences department, reveals a completely alternative non-cannabis plant-derived production system. According to Xinteza this system is capable of efficient and flawless end-to-end cannabinoid biosynthesis. This exclusive non-cannabis alternative novel IP was successfully utilized and implemented by the company to its microbial cannabinoid bio-production newly developed proprietary platform.

The company says this newly discovered alternative gene pool includes a novel prenyltransferase enzyme, featuring superior kinetics and improved flexibility to solve major bottlenecks hindering cannabinoid biosynthesis. Furthermore, this alternative non-cannabis plant-derived system also includes a novel sub-set of cannabinoid-glycosylation enzymes and genes, enabling the biosynthesis of true water-soluble cannabinoids to revolutionize beverages, cosmetics, and pharma.

Xinteza API Ltd. operates in collaboration with the Weizmann Institute of Science and the Plant Metabolomics lab headed by Aharoni, and based on a license signed with Yeda, the commercial arm of the Weizmann Institute.

Photo by Louis Reed on Unsplash

Related News

Xinteza Discovers Novel Key Enzyme For Cannabinoid Biosynthesis

Beating The Nature's Way: Bio-Synthesized Cannabinoid Production Achieved By Xinteza